Untitled Letters 2022
These letters are supplied by the CDER Freedom of Information Office and only covers Office of Prescription Drug Promotion's untitled letters. The agency may have redacted or edited some of the letters to remove confidential information.
Office of Prescription Drug Promotion
| Company / Individual | Product / Issue | Issued Date |
|---|---|---|
|
Eli Lilly & Company
|
BLA 125469 TRULICITY® (dulaglutide) injection, for subcutaneous use |
01/19/2022 |
|
Bausch Health Companies Inc
|
NDA 209354 DUOBRII (halobetasol propionate and tazarotene) lotion, for topical use | 3/31/2022 |
|
Althera Pharmaceuticals
|
NDA 213072 ROSZET (rosuvastatin ezetimibe) tables, for oral use | 6/2/2022 |
